CBD is the second most abundant cannabinoid in cannabis and acts without psychoactive effects. This article covers its mechanism of action, medical applications, products, legal status, and separates myths from evidence.
Cannabidiol (CBD) is the second most abundant cannabinoid in cannabis and has emerged as one of the most discussed bioactive compounds in recent years. Unlike THC, CBD has no psychoactive properties – it causes neither euphoria nor altered consciousness. Yet CBD is far from inert: it interacts with multiple biological systems and shows a broad spectrum of effects in scientific studies.
## Discovery
CBD was first isolated in 1940 by Roger Adams at the University of Illinois. Its complete chemical structure was elucidated in 1963 by Raphael Mechoulam – one year before he also decoded THC's structure. CBD and THC share the same molecular formula (C₂₁H₃₀O₂) and are structural isomers.
## Mechanism of Action
CBD's pharmacology is complex and involves multiple molecular targets simultaneously:
**TRPV1 receptors:** CBD activates these pain and heat-sensing ion channels, explaining analgesic and anti-inflammatory effects. **5-HT1A receptors:** CBD acts as a partial agonist at this serotonin receptor subtype, contributing to anxiolytic effects. **FAAH inhibition:** CBD inhibits the enzyme that breaks down anandamide (the endogenous "bliss molecule"), indirectly increasing anandamide levels. **Negative allosteric CB1 modulation:** CBD binds to a different site on CB1 receptors than THC, potentially dampening THC's effects. **GPR55 antagonism:** This receptor, sometimes called CB3, is involved in pain modulation and possibly cancer cell proliferation. **Adenosine reuptake inhibition:** CBD increases adenosine availability, contributing to anti-inflammatory and sleep-promoting effects.
## Medical Applications with Evidence
**Epilepsy (Epidiolex):** The strongest evidence base. CBD-based Epidiolex was approved by the FDA in 2018 for Dravet syndrome, Lennox-Gastaut syndrome, and TSC – rare, severe pediatric epilepsy forms where it significantly reduces seizure frequency.
**Anxiety disorders:** Multiple clinical studies show anxiolytic effects. A 2011 double-blind study demonstrated that 600 mg CBD significantly reduced social anxiety in patients with social phobia.
**Inflammation:** CBD inhibits multiple inflammatory mediators. Clinical trials for arthritis and inflammatory bowel disease are ongoing.
**Sleep:** CBD may improve sleep primarily by reducing anxiety and pain, with adenosine modulation playing a secondary role.
## CBD Products
Available forms: oils/tinctures (sublingual, bioavailability 13–19%), capsules (oral, 6–15%), flowers (inhaled, up to 31%), and topicals (local application, minimal systemic absorption). Product types range from CBD isolate (>99% pure CBD) to broad spectrum (CBD + other cannabinoids, no THC) to full spectrum (all natural compounds including trace THC).
## Dosing
10–25 mg/day for general wellness; 25–75 mg/day for anxiety; up to 600 mg in clinical studies. The principle: start low, go slow. CBD exhibits a somewhat biphasic dose-response curve.
## Drug Interactions
CBD inhibits CYP3A4 and CYP2C19 liver enzymes, potentially altering blood levels of medications including anticoagulants, antiepileptics, and immunosuppressants. Medical consultation is essential before combining CBD with existing medications.
## Quality Criteria
Look for: independent laboratory Certificate of Analysis (CoA) verifying CBD content, THC content, pesticides, heavy metals, and solvent residues; CO₂ extraction methods; EU-certified organic hemp; and transparent manufacturers who make lab reports publicly available.
## The Entourage Effect
The "entourage effect" hypothesis proposes that cannabinoids, terpenes, and other plant compounds work synergistically. CBD may modulate THC's effects while terpenes like limonene and linalool contribute their own anxiolytic properties. Scientific evidence is accumulating but not yet definitive.
## Separating Facts from Myths
CBD is not a cure-all, is not addictive (WHO classification), does not cause a high, and more is not always better. However, it does have genuine pharmacological properties and growing evidence for specific medical applications. Informed, realistic expectations are essential.
Related Articles
Tetrahydrocannabinol (THC): The Most Important Psychoactive Cannabinoid
THC is the primary psychoactive compound of the cannabis plant. This article explains its discovery, mechanism of action, medical applications, metabolism, detection times, and current research.
Cannabigerol (CBG): The Mother of All Cannabinoids
CBG is the precursor to all other cannabinoids and is called the "mother of all cannabinoids." This article explains CBGA biosynthesis, its pharmacological profile, current research findings, and CBG-rich strains.
The Endocannabinoid System: The Body's Unknown Regulatory System
The endocannabinoid system (ECS) is one of the most important regulatory systems in the human body. This article explains its discovery, components (anandamide, 2-AG, CB1, CB2), functions, and clinical endocannabinoid deficiency.
What Are Terpenes? Definition, Chemistry and Effects
Terpenes are the aromatic compounds of the cannabis plant. This article explains their chemical basis, role in nature, the entourage effect, and why the terpene profile matters more than indica or sativa.
Safer Use Rules for Cannabis
Comprehensive rules for low-risk cannabis use – covering set and setting, dosing, consumption methods, tolerance management, polydrug use, and emergency response.